TY - JOUR
T1 - Delivery technologies for cancer immunotherapy
AU - Riley, Rachel S.
AU - June, Carl H.
AU - Langer, Robert
AU - Mitchell, Michael J.
N1 - Funding Information:
M.J.M. is supported by a Burroughs Wellcome Fund Career Award at the Scientific Interface, a US National Institutes of Health (NIH) Director’s New Innovator Award (DP2 TR002776) and a grant from the American Cancer Society (129784-IRG-16-188-38-IRG). R.S.R. is supported by an NIH T32 multidisciplinary training grant. The authors’ work is supported in part by Cancer Center Support (core) Grant P30-CA14051 from the US National Cancer Institute and a grant from the Koch Institute’s Marble Centre for Cancer Nanomedicine (to R.L.).
Publisher Copyright:
© 2018, Springer Nature Limited.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Immunotherapy has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug approvals has been increasing, with numerous treatments in clinical and preclinical development. However, a key challenge in the broad implementation of immunotherapies for cancer remains the controlled modulation of the immune system, as these therapeutics have serious adverse effects including autoimmunity and nonspecific inflammation. Understanding how to increase the response rates to various classes of immunotherapy is key to improving efficacy and controlling these adverse effects. Advanced biomaterials and drug delivery systems, such as nanoparticles and the use of T cells to deliver therapies, could effectively harness immunotherapies and improve their potency while reducing toxic side effects. Here, we discuss these research advances, as well as the opportunities and challenges for integrating delivery technologies into cancer immunotherapy, and we critically analyse the outlook for these emerging areas.
AB - Immunotherapy has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug approvals has been increasing, with numerous treatments in clinical and preclinical development. However, a key challenge in the broad implementation of immunotherapies for cancer remains the controlled modulation of the immune system, as these therapeutics have serious adverse effects including autoimmunity and nonspecific inflammation. Understanding how to increase the response rates to various classes of immunotherapy is key to improving efficacy and controlling these adverse effects. Advanced biomaterials and drug delivery systems, such as nanoparticles and the use of T cells to deliver therapies, could effectively harness immunotherapies and improve their potency while reducing toxic side effects. Here, we discuss these research advances, as well as the opportunities and challenges for integrating delivery technologies into cancer immunotherapy, and we critically analyse the outlook for these emerging areas.
UR - http://www.scopus.com/inward/record.url?scp=85059772897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059772897&partnerID=8YFLogxK
U2 - 10.1038/s41573-018-0006-z
DO - 10.1038/s41573-018-0006-z
M3 - Review article
C2 - 30622344
AN - SCOPUS:85059772897
VL - 18
SP - 175
EP - 196
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
SN - 1474-1776
IS - 3
ER -